Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxalutamide vs placebo in mCRPC after abiraterone and docetaxel failure
CTR20180849Phase 3Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of proxalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Kintor Pharmaceutical Limited. Started Jul 2018; status: completed.
02
Drugs
proxalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20180849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180849.